Wolters Kluwer Lippincott Williams & Wilkins Health Philadelphia Baltimore New York«London Buenos Aires Hong Kong Sydney Tokyo



Similar documents
Health Outcomes and Pharmacoeconomics

Cost-Effectiveness of Influenza Vaccines

Cost-Benefit and Cost-Effectiveness Analysis. Kevin Frick, PhD Johns Hopkins University

Evidence-based Health Policies for Medical Devices and Diagnostics in Asia. Outline of Presentation

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip

Cost-Effectiveness Analysis (CEA)

Medication Therapy Management (MTM) Program

Hindrik Vondeling Department of Health Economics University of Southern Denmark Odense, Denmark

Choices in Methods for Economic Evaluation

Economic Evaluation for Global Health Programs

A Comprehensive Survey of Managed Care Organization (MCO) Medication Adherence Intervention Programs Part I: Patient and Intervention Targeting

EVALUATION OF PUBLIC HEALTH INTERVENTIONS

Orsolya Balogh. Economic consideration of the implementation of biotechnological therapies in chronic diseases

Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans

Measuring Outcomes for NC Local Health Departments: Preliminary Results

HEALTH ECONOMICS BY FRANK A. SLOAN AND CHEE-RUEY HSIEH THE MIT PRESS CAMBRIDGE, MASSACHUSETTS LONDON, ENGLAND

An Assessment of the Cost-Utility of Therapy for Psoriasis

Medicare Advantage - Stride Quality Program NH Medical Director Meeting March 2015

Selection of Medicaid Beneficiaries for Chronic Care Management Programs: Overview and Uses of Predictive Modeling

Circular 56 of 2015: Accounting for accredited managed care services based on comments received from the industry

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Long-term Comparative Effectiveness of Rheumatoid Arthritis Treatment Strategies

Formulary Management

HEALTH CARE COSTS 11

11/2/2015 Domain: Care Coordination / Patient Safety

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.

ECONOMICS 2 HEALTHCARE MANAGERS THIRD EDITION ROBERT H. LEE AUPHA. Health Administration Press, Chicago, Illinois

Concepts in Economic Evaluation

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

PRINCIPLES AND METHODS OF PHARMACY MANAGEMENT

Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective

What is a QALY? What is...? series. Second edition. Health economics. Supported by sanofi-aventis

Obesity: The Business Case for Intervention

Report on comparing quality among Medicare Advantage plans and between Medicare Advantage and fee-for-service Medicare

Program th Clinical Pharmacy Week (CPW 2015) September 13th 16th, 2015 Vienna, Austria

WHAT IS MEDICAL MANAGEMENT? WHAT IS THE PURPOSE OF MEDICAL MANAGEMENT?

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Reimbursement for Medical Products: Ensuring Marketplace

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Princeton University Prescription Drug Plan Summary Plan Description

How To Weigh Data From A Study

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Specialty Drug Care: Case management services in Quebec

The Benefits of Disease Therapy Management (DTM) for Multiple Sclerosis (MS)

PBM s: Helping to Improve MA-PD Star Scores. James Brehany PharmD, PA-C, JD Associate Vice President, Pharmacy Services PerformRx

How Is OnabotulinumtoxinA Reimbursed For Chronic Migraine? Impact Of FDA Approval And The New CPT Code

David K. Chatkoff, Ph.D. Curriculum Vitae

Summary 1. Comparative-effectiveness

How To Understand The Pharmacology Of The Pharmaceutical Industry

MASTER OF HEALTH POLICY AND MANAGEMENT

The Centers for Medicare & Medicaid Services (CMS) strives to make information available to all. Nevertheless, portions of our files including

Knowledge Synergies The New Paradigm of Innovation. Israel Makov

Getting Clinicians Involved: Testing Smartphone Applications to Promote Behavior Change in Health Care

Australian Healthcare Reform

THE ECONOMICS OF HEALTH AND HEALTH CARE

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

U.S. Food and Drug Administration

What are health utilities?

Managed Care Pharmacy. Objectives. Health Plans Some Background 4/7/2015. Kim Moon, PharmD Spring 2015

Chapter 6. Outcome Definition and Measurement

STATISTICAL BRIEF #167

NEW ZEALAND FINANCIAL ACCOUNTING

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Special Committee on Aging. Hearing on:

Pharmacoeconomics: basic concepts and terminology

White Paper. Medicare Part D Improves the Economic Well-Being of Low Income Seniors

DOELMATIGHEID: TECHNIEK & PRAKTIJK

Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business

Introduction to health economics for physicians

HEDIS, STAR Performance Metrics. Sheila Linehan, RN,MPH, CPHQ Director of QM, Horizon BCBSNJ July 16, 2014

Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 Reporting Year

Oncology Knowledge Bulletin. Strategies in oncology: Spotlight on clinical pathways

Focal therapy for prostate cancer: seriously or seriously? Disclosures

WELCOME TO OCCUPATIONAL THERAPY CARE OF THE ELDERLY TEAM

Crossing the Doughnut Hole: The Effects of the Medicare Drug Coverage Gap for Patients who Require High-cost Medications

ANNALS OF HEALTH LAW Advance Directive VOLUME 20 SPRING 2011 PAGES Value-Based Purchasing As a Bridge Between Value and Access

Re: CMS-1345-P; Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations; Proposed Rule

Intervention Databases: A Tool for Documenting Student Learning and Clinical Value. Program Overview. Background

What is an ACO? What forms of organizations may become an ACO? IAMSS 30 th Annual Education Conference Pearls of Wisdom

CONTEMPORARY DIRECT & INTERACTIVE MARKETING

Atlanta, GA Atlanta Marriott at Perimeter Center

Pharmacoeconomic, Epidemiology, and Pharmaceutical Policy and Outcomes Research (PEPPOR) Graduate Program

Medicare Advantage and Part D Proposed Rule for Contract Year 2015 Prepared for Healthcare Leadership Council. January 2014 Avalere Health LLC 1

PCHC FACTS ABOUT HEALTH CONDITIONS AND MOOD DIFFICULTIES

N656: ADVANCED PRACTICE NURSING: PRIMARY CARE II

Issue Brief: Minimum Medical Loss Ratio Requirements

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014

Michelle Pinelle RN, BSN, CCRN & Jamie Roney RN, BSN, CCRN Texas Tech University Health Sciences Center, Lubbock, Texas

Telehealth: A tool for the 21 st century. Definitions

LTC Pharmacy Setting B/D Coverage. Because most LTC facilities are not considered a beneficiary s home 3

Health economic analyses based on register data. Psoriasis and Psoriatic Arthritis as examples

Osteoporosis and Vertebral Compression (Spinal) Fractures Fact Sheet

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Evidence Based Medicine Health Information Infrastructure Transparency and Payment Reform. Ward B. Hurlburt, M.D. October 12, 2002

GLOBAL ACCESS LICENSING FRAMEWORK

1. Comparative effectiveness of alemtuzumab

Guidelines on Health Economic Evaluation

CDEC RECORD OF ADVICE

The Economic Impact and Cost-Effectiveness of Glucose Monitoring

Integrated Physical & Behavioral Health. A Business Opportunity for Employers

Transcription:

Essentials of Pharmacoeconomics SECOND EDITION Karen L. Rascati, PhD Eckerd/Turley Centennial Professor of Health Outcomes and Pharmacy Practice University of Texas College of Pharmacy Austin, Texas Wolters Kluwer Lippincott Williams & Wilkins Health Philadelphia Baltimore New York«London Buenos Aires Hong Kong Sydney Tokyo

Contents PART I BASIC TOPICS CHAPTER 1 Introduction 1 Pharmacoeconomics What Is It? 1 Why Is Pharmacoeconomics Important? 2 Relationship of Pharmacoeconomics to Other Research 3 Types of Pharmacoeconomic Studies 4 SUMMARY 8 QUESTIONS/EXERCISES 8 REFERENCES 8 SUGGESTED READINGS 9 CHAPTER 2 Measuring and Estimating Costs 10 Costing Terms 10 Cost Categorization 11 Alternative Method of Categorization 13 Perspective 13 Timing Adjustments for Costs 14 Resources for Cost Estimations 18 SUMMARY 21 QUESTIONS/EXERCISES 24 REFERENCES 24 SUGGESTED READINGS 25 CHAPTER 3 Critiquing Research Articles 26 Appropriateness of Methods of Analysis 26 Questions to Use When Critiquing Research Articles 26 SUMMARY 32 QUESTIONS/EXERCISES 32 REFERENCES 33 SUGGESTED READINGS 34 CHAPTER 4 Cost-Minimization Analysis 35 Overview 35 SUMMARY 36 Composite Article: CMA Anti-nausea 37 QUESTIONS/EXERCISES 42 REFERENCES 44 SUGGESTED READINGS 44 xiii

xiv CONTENTS CHAPTERS Cost-Effectiveness Analysis 45 Overview 45 Presentation of Costs and Effectiveness 46 Cost-Effectiveness Grid 47 Cost-Effectiveness Plane 49 Intermediate Outcomes versus Primary Outcomes 50 Efficacy versus Effectiveness S3 Consensus and Debate 54 SUMMARY 55 Composite Article 1: CEA Asthma 55 Composite Article 2: CEA Post-Myocardial Infarction Heart Failure 63 QUESTIONS/EXERCISES 70 REFERENCES 71 SUGGESTED READINGS 71 CHAPTER 6 Cost-Utility Analysis 72 Overview 72 Steps in Calculating QALYs 73 Trends in CUA Analyses 80 SUMMARY 85 Composite Article 1: CUA Oncology 85 Composite Article 2: CUA Immunosuppression 92 QUESTIONS/EXERCISES 99 REFERENCES 101 SUGGESTED READINGS 102 CHAPTER? Cost-Benefit Analysis 103 Definition and History 103 Advantages and Disadvantages of Cost-Benefit Analysis 104 Conducting a CBA 105 Difference between Costs and Benefits 106 Measuring Indirect and Intangible Benefits 106 Calculating Results of Costs and Benefits 112 SUMMARY 114 Composite Article 1: CBA Vaccination 117 Composite Article 2: CBA Alzheimer's Disease 123 QUESTIONS/EXERCISES 128 REFERENCES 129 SUGGESTED READINGS 130 CHAPTER 8 Health-Related Quality of Life: Health Status Measures 131 Definitions 132 HRQoL Measures versus Utility Measures 132 Domains of Health Status 136 Assessing HRQoL Instruments 138 Pharmacoeconomics and HRQoL Measures 141

Contents XV Preference-Based Classification Systems 141 Patient-Reported Outcomes 143 SUMMARY 144 Composite Article 1: HRQoL Rheumatoid Arthritis 144 Composite Article 2: HRQoL Chronic Low Back Pain 152 QUESTIONS/EXERCISES 161 REFERENCES 165 SUGGESTED READINGS 166 PART II ADVANCED TOPICS CHAPTER 9 Decision Analysis 169 What Is Decision Analysis? 169 Steps in Decision Analysis 169 Threshold Analysis 175 SUMMARY 177 Composite Article 1: Decision Analysis Migraine 178 Composite Article 2: Decision Analysis Erectile Dysfunction 185 QUESTIONS/EXERCISES 191 REFERENCES 192 SUGGESTED READINGS 192 CHAPTER 10 Markov Modeling 193 Overview 193 Steps in Markov Modeling 193 Disadvantages of Markov Modeling 200 Advanced Issues 201 Other Advanced Topics 202 SUMMARY 203 Composite Article 1: Markov Modeling Initiation of HIV Therapy 204 ANSWERS 212 Composite Article 2: Markov Modeling Phosphate Binders 213 ANSWERS 220 QUESTIONS/EXERCISES 221 REFERENCES 223 SUGGESTED READINGS 224 CHAPTER 11 Retrospective Databases 225 Overview of Retrospective Databases 225 Randomized, Controlled Trials 225 Observational Studies 226 Advantages and Disadvantages ofrcts 226 Advantages and Disadvantages of Observational Studies 227 Types of Retrospective Databases 228 Insurance and Claims Records 230 Critiquing Retrospective Database Studies 230

xvi CONTENTS SUMMARY 232 Composite Article 1: Retrospective Database COPD 232 Composite Article 2: Retrospective Database Bisphosphonates 240 QUESTIONS/EXERCISES 244 REFERENCES 244 SUGGESTED READINGS 245 CHAPTER 12 Pharmacy Services 246 What Are Pharmacy Services? 246 History of Pharmacy Services 247 Review of the Research 247 Issues in Valuing Pharmacy Services 249 Medicare Medication Therapy Management 250 SUMMARY 252 Composite Article: Pharmacy Services 253 QUESTIONS/EXERCISES 260 REFERENCES 262 SUGGESTED READINGS 263 CHAPTER 13 International Perspective 264 Health Care Expenditures 264 Comparability of Pharmacoeconomic Results between Countries 266 History of Pharmacoeconomic Guideline Development 266 SUMMARY 271 QUESTIONS/EXERCISES 271 REFERENCES 273 SUGGESTED READINGS 274 CHAPTER M Future Issues 275 Application of Pharmacoeconomics in the United States 275 Federal Agencies 275 Private Health Care Plans 276 Barriers to Pharmacoeconomics in the United States 277 Other Future Issues 278 SUMMARY 279 QUESTIONS/EXERCISES 280 REFERENCES 280 SUGGESTED READINGS 282 Glossary 283 Index 289